Bluenote Health is a technology company.
Bluenote Health has raised $10.0M across 1 funding round.
Bluenote Health has raised $10.0M in total across 1 funding round.
Bluenote Health is a San Francisco-based medtech company developing an AI platform that automates critical workflows for life sciences organizations, including pharma, medical devices, CROs, and CDMOs.[1][2][3] It generates first drafts of regulatory documents like INDs, NDAs, BLAs, CSRs, CMC, and PMAs, while offering AI agents for lab operations, data analysis, and quality control, accelerating processes by 50-75% to speed up therapy delivery to patients.[1][3][4] Serving enterprise clients with enterprise-grade security (SOC 2 Type II, HIPAA, SAML SSO, zero data retention), Bluenote has raised $10M in funding, including from Lux Capital, and employs under 25 people with strong early momentum from industry veterans.[1][2][5]
Bluenote Health was co-founded by Fatima Sabar (CEO, with biomedical research and Color Health experience) and Katsuya Noguchi (CTO, also ex-Color Health), both former executives at Color Health.[4][5] Sabar, who spoke at Fierce Biotech Week, drew from her background in biomedical research to address administrative burdens in drug development, aiming to restore scientists' focus on innovation.[4] The company emerged recently, securing $10M in funding announced in 2025 from investors like Lux Capital, with team members from Google, Twitter, Pfizer, and Amgen providing pivotal expertise for rapid traction in AI-driven life sciences.[1][2][4][5]
Bluenote stands out in the AI-for-life-sciences space through these key strengths:
Bluenote rides the AI transformation in life sciences, targeting pre-AI era bottlenecks in regulatory submissions and lab operations amid rising drug development costs and timelines.[1][3][4] Timing aligns with generative AI maturity and industry shift to AI-first operations, fueled by market forces like talent shortages, data explosion, and demands for faster therapies—enabling 50-75% acceleration where manual work dominates.[1][4] It influences the ecosystem by partnering with top pharma and devices firms, promoting traceable AI adoption, and paving the way for expansions like AI-driven clinical trials and patient engagement, ultimately benefiting patients through quicker innovations.[3][4]
Bluenote is poised to expand from documentation to full drug development OS, with AI agents tackling clinical recruitment, multilingual patient interactions, and real-time data integration.[4] Trends like accelerating AI hardware, regulatory embrace of digital tools, and enterprise AI demand will propel growth, especially as competitors lag in domain expertise.[4] Its influence may evolve by setting standards for secure, scalable life sciences AI, drawing more talent and funding—transforming how therapies reach patients sooner, as its platform already promises.
Bluenote Health has raised $10.0M in total across 1 funding round.
Bluenote Health's investors include 468 Capital, 7wire Ventures, Andreessen Horowitz, Artichoke Capital, Catalio Capital, Cherubic Ventures, Dragonfly Capital Partners, Electric Capital, Lux Capital, Paradigm, Placeholder, Refactor Capital.
Bluenote Health has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Venture Round in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $10.0M Venture Round | 468 Capital, 7wire Ventures, Andreessen Horowitz, Artichoke Capital, Catalio Capital, Cherubic Ventures, Dragonfly Capital Partners, Electric Capital, Lux Capital, Paradigm, Placeholder, Refactor Capital, Robot Ventures, Rocketship.vc, Sequoia Capital, Sherpalo Ventures, The Hit Forge, XFactor Ventures, Ameet Patel, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Baris Gultekin, Biz Stone, Dylan Field, Gokul Rajaram, Josh Elman, Kunal Shah, Varsha Rao |